Prevención y tratamiento de la enfermedad venooclusiva hepática

Carreras, 2000, Veno-occlusive disease of the liver after hemopoietic cell transplanttation, Eur J Haematol, 64, 281, 10.1034/j.1600-0609.2000.9r200.x

McDonald, 1987, Liver disease after human marrow transplantation, Semin Liv Dis, 7, 210, 10.1055/s-2008-1040578

Bearman, 1995, The syndrome of hepatic veno-occlusive disease after marrow transplantation, Blood, 85, 3005, 10.1182/blood.V85.11.3005.bloodjournal85113005

DeLeve, 2002, Toxic injury to hepatic sinusoids:sinusoidal obstruction syndrome (veno-occlusive disease), Semin Liver Dis, 22, 27, 10.1055/s-2002-23204

DeLeve, 2006, Rat liver endothelial cells isolated by anti-CD31 immunomagnetic separation lack fenestrae and sieve plates, Am J Physiol Gastrointest Liver Physiol, 291, G1187, 10.1152/ajpgi.00229.2006

Shulman, 1984, Venoocclusive disease of the liver after marrow transplantation:Histological correlates of clinical signs and symptoms, Hepatology, 19, 1171, 10.1002/hep.1840190515

DeLeve, 1996, Cellular target of cyclophosphamide toxicity in the murine liver-role of glutathione and site of metabolic activation, Hepatology, 24, 830, 10.1002/hep.510240414

Teicher, 1988, Glutathione monoethyl ester can selectively protect liver from high dose BCNU or cyclophosphamide, Cancer, 62, 1275, 10.1002/1097-0142(19881001)62:7<1275::AID-CNCR2820620705>3.0.CO;2-I

Pessayre, 1991, Drug-induced liver injury, 2, 873

Strasser, 1999, Gastrointestinal and hepatic complications, 627

McDonald, 1993, Veno-occlusive disease of the liver and multiorgan failure after Bone Marrow Transplantation:A cohort study of 355 patients, Ann Intern Med, 118, 255, 10.7326/0003-4819-118-4-199302150-00003

Carreras, 1998, Incidence and outcome of hepatic veno-occlusive disease (VOD) after blood and marrow transplantation (BMT):a prospective cohort study of the European group for Blood and Marrow Transplantation (EBMT), Blood, 92, 3599

McDonald, 1985, The clinical course of 53 patients with venocclusive disease of the liver after marrow transplantation, Transplantation, 39, 603, 10.1097/00007890-198506000-00005

Bearman, 1993, Venoocclusive disease of the liver:development of a model for predicting fatal outcome after marrow transplantation, J Clin Oncol, 11, 1729, 10.1200/JCO.1993.11.9.1729

Morgan, 1991, The toxicity of busulphan and cyclophosphamide as the preparative regimen for bone marrow transplantation, Br J Haematol, 77, 529, 10.1111/j.1365-2141.1991.tb08621.x

Yeager, 1992, Optimization of busulfan dosage in children undergoing bone marrow transplantation:A pharmacokinetic study of dose escalation, Blood, 80, 2425, 10.1182/blood.V80.9.2425.2425

Lee, 2005, Decreased incidence of hepatic veno-occlusive disease and fewer hemostatic derangements associated with intravenous busulfan vs oral busulfan in adults conditioned with busulfan + cyclophosphamide for allogeneic bone marrow transplantation, Ann Hematol, 84, 321, 10.1007/s00277-004-0982-4

Deeg, 1986, Marrow transplantation for nonlymphophastic leukemia in first remission:toxicity and long-term follow-up of patients conditioned with single dose or fractionated total body irradiation, Bone Marrow Transplant, 1, 151

Ozsahin, 1992, Total-body irradiation before bone marrow transplantation. Results of two randomized instantaneous dose rates in 157 patients, Cancer, 69, 2853, 10.1002/1097-0142(19920601)69:11<2853::AID-CNCR2820691135>3.0.CO;2-2

Ramasamy, 2006, Incidence and management of hepatic venoocclusive disease in 237 patients undergoing reduced-intensity conditioning (RIC) haematopoietic stem cell transplantation (HSCT), Bone Marrow Transplant, 38, 823, 10.1038/sj.bmt.1705528

Hägglund, 1998, Noethisterone treatment, a major risk factor for veno-occlusive disease in the liver after allogeneic bone marrow transplantation, Blood, 92, 4568, 10.1182/blood.V92.12.4568

Chevallier, 2010, Prior treatment with gemtuzumab ozogamicin and the risk of veno-occlusive disease after allogeneic haematopoietic stem cell transplantation, Bone Marrow Transplant, 45, 165, 10.1038/bmt.2009.153

Marsa-Vila, 1991, Prophylactic heparin does not prevent liver veno-occlusive disease following autologous bone marrow transplantation, Eur J Haematol, 47, 346, 10.1111/j.1600-0609.1991.tb01859.x

Attal, 1992, Prevention of hepatic veno-occlusive disease after bone marrow transplantation by continuous infusion of low-dose heparin:A prospective, randomized trial, Blood, 79, 2834, 10.1182/blood.V79.11.2834.bloodjournal79112834

Or, 1996, Low molecular weight heparin for the prevention of veno-occlusive disease of the liver in bone marrow transplantation patients, Transplantation, 61, 1067, 10.1097/00007890-199604150-00014

Forrest, 2003, Low molecular weight heparin for the prevention of hepatic veno-occlusive disease (VOD) alter hematopoietic stem cell transplantation:a prospective phase II study, Bone Marrow Transplant, 31, 1143, 10.1038/sj.bmt.1704087

Gluckman, 1990, Use of prostaglandin E1 for prevention of liver veno-occlusive disease in leukaemic patients treated by allogeneic bone marrow transplantation, Br J Haematol, 74, 277, 10.1111/j.1365-2141.1990.tb02583.x

Bearman, 1993, Prostaglandin E1 for prevention of hepatic veno-occlusive disease:results of a phase I study, Br J Haematol, 84, 724, 10.1111/j.1365-2141.1993.tb03152.x

Essell, 1998, Ursodiol prophylaxis against hepatic complications of allogeneic stem cell transplantation. A randomized. double-blind, placebo-controlled trial, Ann Intern Med, 128, 975, 10.7326/0003-4819-128-12_Part_1-199806150-00002

Ohashi, 2000, The Japanese multicenter open randomized trial of ursodeoxycholic acid prophylaxis for hepatic veno-occlusive disease after stem cell transplantation, Am J Hematol, 64, 32, 10.1002/(SICI)1096-8652(200005)64:1<32::AID-AJH6>3.0.CO;2-N

Ruutu, 2002, Ursodeoxycholic acid for the prevention of hepatic complications in allogeneic stem cell transplantation, Blood, 100, 1977, 10.1182/blood-2001-12-0159

Clift, 1993, A randomized controlled trial of pentoxifylline for the prevention of regimen-related toxicities in patients undergoing allogeneic marrow transplantation, Blood, 82, 2025, 10.1182/blood.V82.7.2025.2025

Lakshminarayanan, 2010, Low incidence of hepatic veno-occlusive disease in pediatric patients undergoing hematopoietic stem cell transplantation attributed to a combination of intravenous heparin, oral glutamine, and ursodiol at a single transplant institution, Pediatr Transplant, 14, 618, 10.1111/j.1399-3046.2009.01285.x

Ringdén, 2000, N-acetylcysteine for hepatic veno-occlusive disease after allogeneic stem cell transplantation, Bone Marrow Transplant, 25, 993, 10.1038/sj.bmt.1702387

Barkholt, 2008, A prospective randomized study using N-acetyl-L-cysteine for early liver toxicity after allogeneic hematopoietic stem cell transplantation, Bone Marrow Transplant, 41, 785, 10.1038/sj.bmt.1705969

Chalandon, 2004, Prevention of veno-occlusive disease with defibrotide after allogeneic stem cell transplantation, Biol Blood Marrow Transplant, 10, 347, 10.1016/j.bbmt.2004.01.002

Corbacioglu, 2006, Stem cell transplantation in children with infantile osteopetrosis is associated with a high incidence of VOD, which could be prevented with defibrotide, Bone Marrow Transplant, 38, 547, 10.1038/sj.bmt.1705485

Dignan, 2007, Prophylactic defibrotide in allogeneic stem cell transplantation:minimal morbidity and zero mortality from veno-occlusive disease, Bone Marrow Transplant, 40, 79, 10.1038/sj.bmt.1705696

Versluys, 2004, Prophylaxis with defibrotide prevents veno-occlusive disease in stem cell transplantation after gemtuzumab ozogamicin exposure, Blood, 103, 1968, 10.1182/blood-2003-10-3612

Ho, 2008, Hepatic veno-occlusive disease after hematopoietic stem cell transplantation:update on defibrotide and other current investigational therapies, Bone Marrow Transplant, 41, 229, 10.1038/sj.bmt.1705899

Corbacioglu, 2010, Defibrotide prevents hepatic VOD and reduces significantly VOD-associated complicatins in children at high risk:final results of a prospective phase II/III muticentre study, Bone Marrow Transplant, 45, S1

Palomo, 2011, Defibrotide prevents the activation of macrovascular and microvascular endothelia caused by soluble factors released to blood by autologous hematopoietic stem cell transplantation, Biol Blood Marrow Transplant, 17, 497, 10.1016/j.bbmt.2010.11.019

Eissner, 2005, Oligotide, a defibrotide derivative, protects human microvascular endothelial cells against fludarabine-induced activation, damage and allogenicity, Bone Marrow Transplant, 35, 915, 10.1038/sj.bmt.1704930

Hennan, 2008, Effect of tiplaxtinin (PAI-039), an orally bioavailable PAI-1 antagonist, in a rat model of thrombosis, J Thromb Haemost, 6, 1558, 10.1111/j.1538-7836.2008.03063.x

Agbani, 2011, Peroxynitrite stimulates pulmonary artery endothelial and smooth muscle cell proliferation:Involvement of ERK and PKC, Pulm Pharmacol Ther, 24, 100, 10.1016/j.pupt.2010.09.003

Schmitt, 2009, Modulation of endothelial nitric oxide by plant-derived products, Nitric Oxide, 21, 77, 10.1016/j.niox.2009.05.006

Tefferi, 2001, Charcoal hemofiltration for hepatic veno-occlusive disease after hematopoietic stem cell transplantation, Bone Marrow Transplant, 28, 997, 10.1038/sj.bmt.1703267

Nimer, 1990, Successful treatment of hepatic venoocclusive disease in a bone marrow transplant patient with orthotopic liver transplantation, Transplantation, 49, 819, 10.1097/00007890-199004000-00035

Bearman, 1991, Prostaglandin E1 for prevention of hepatic veno-occlusive disease:results of a phase I study, Exp Hematol, 19, 567

Bearman, 1997, Treatment of hepatic venocclusive disease with recombinant human tissue plasminogen activator and heparin in 42 marrow transplant patients, Blood, 89, 1501, 10.1182/blood.V89.5.1501

Morris, 1997, Antithombin-III for the treatment of chemotherapy-induced organ dysfunction following bone marrow transplantation, Bone Marrow Transplant, 20, 871, 10.1038/sj.bmt.1700985

Haire, 1998, A prospective randomized double-blind trial of antithrombin III concentrate in the treatment of multiple-organ dysfuntion syndrome during hematopoietic stem cell transplantation, Biol Blood Marrow Transplant, 4, 142, 10.1016/S1083-8791(98)50003-1

Ibrahim, 2004, Anti-thrombin III in the management of hematopoietic stem-cell transplantation-associated toxicity, Ann Pharmacother, 38, 1053, 10.1345/aph.1D235

Eber, 2007, Favorable response of pediatric stem cell recipients to human protein C concentrate substitution for veno-occlusive disease, Pediatr Transplant, 11, 49, 10.1111/j.1399-3046.2006.00612.x

Larocca, 2008, Defibrotide: a review on clinical use and future development, Expert Opin Biol Ther, 8, 1201, 10.1517/14712598.8.8.1201